Fibromyalgia Treatment Market size is estimated to reach USD 536 million by the end of 2033, growing at a CAGR of 9% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of fibromyalgia treatment was over USD 190 million. The growth of the market is primarily ascribed to the worldwide escalating load of chronic pain. Fibromyalgia, according to researchers, increases painful sensations by altering how the brain and spinal cord receive painful and non-painful impulses. As per the World Health Organization (WHO), nearly 1.71 billion people around the world have been suffering from musculoskeletal disorders.
Fibromyalgia, commonly known as fibromyalgia syndrome, is a severe neurologic condition that results in immense pain throughout the body. This condition affects people physically, intellectually, and socially and causes exhaustion, musculoskeletal pain, and localized discomfort. Furthermore, there are only a few drugs, such as milnacipran, and pregabalin which are prescribed for fibromyalgia treatment. Globally rising occurrence of musculoskeletal disorder is leading to increased chances of fibromyalgia. According to the National Fibromyalgia Association, fibromyalgia affects an estimated 10 million people in the United States.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~9% |
|
Base Year Market Size (2022) |
~ USD 190 Million |
|
Forecast Year Market Size (2033) |
~ USD 536 Million |
|
Regional Scope |
|
Drug Class (Antidepressants, Antiepileptic, Muscle Relaxants)
The global fibromyalgia treatment market is segmented and analyzed for demand and supply by drug class into antidepressants, antiepileptics, muscle relaxants, and others. Out of the these, types of drug-class antiepileptics segment is estimated to gain the largest market share over the projected time frame. Anticonvulsants, usually referred to as antiepileptic medications, are frequently prescribed to treat epilepsy, and on the other hand, they have also been used to treat fibromyalgia. The FDA has approved the antiepileptic drug pregabalin for the treatment of fibromyalgia. Pregabalin blocks the release of substances P, norepinephrine, and glutamate, which may significantly help fibromyalgia patients feel less pain. Depending on the patient's creatinine clearance, pregabalin must be begun at 75 mg twice daily and gradually increased to 225 mg twice daily. Total daily doses of 300 mg, 450 mg, or 600 mg can lessen pain by more than 30% if the patient can bear the side effects of drowsiness, dry mouth, added weight, and oedema. The market for antidepressants, is anticipated to hold the second largest share over the forecast period. The signs of depression may be lessened with the aid of antidepressants. Additionally, they can help in the treatment of seasonal affective disorder and social anxiety disorder. There is growing evidence that, to a limited extent, antidepressants are effective therapies for fibromyalgia. Antidepressants change specific neurotransmitters in the brain, and these same neurotransmitters play a role in fibromyalgia. One of the most popular forms of treatment is amitriptyline and other tricyclic antidepressants (TCAs). Newer antidepressants have undergone thorough fibromyalgia testing since they are better tolerated than tricyclics. Instead of acting as an antidepressant, cyclobenzaprine, a tricyclic substance that varies from amitriptyline only by one double bond, relaxes the muscles.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
The global fibromyalgia treatment market is also segmented and analyzed for distribution by distribution into retail pharmacies, hospital pharmacies, and online pharmacies. Amongst these three segments, the retail pharmacies segment is expected to garner a significant share. Any pharmacy that dispenses, stocks, or sells prescription drugs to the general public is considered retail pharmacy. Any consumer can pick up their medication at a retail pharmacy without first acquiring a prescription. Moreover, the customers have direct contact with the retailer. A reputable company that sells medicines and related goods is a retail pharmacy. Since hospitalization is not always necessary for fibromyalgia therapy, retail pharmacies are expected to gain market share during the anticipated period. Hospital pharmacies, which were expected to expand at the greatest CAGR, were the second-largest market in 2021. Integrated into the care of a medical facility is the subsection of pharmacy known as a hospital pharmacy. These include residential care institutions, hospitals, outpatient clinics, drug addiction treatment centers, poison control centers, and drug resource centers. The job involves choosing, preparing, storing, compounding, and dispensing drugs for patients in a medical setting. Hospital pharmacies' primary responsibility in patient care is risk management.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Type |
|
|
By Distribution |
|
APAC Market Statistics
The Asia-Pacific market is anticipated to increase steadily throughout the course of the forecast period. Aspects such as the growing number of fibromyalgia patients, along with rising healthcare spending and developing healthcare infrastructure, are predicted to boost the market growth in the Asia Pacific.
North American Market Forecast
The North America fibromyalgia treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. It is backed by the radically increasing prevalence of fibromyalgia, and the rising awareness among people regarding fibromyalgia in the region. As per the Centers for Disease Control and Prevention, fibromyalgia affects approximately 4 million adults in the United States, accounting for approximately 2% of the adult population.
Aptinyx Inc. declared the completion of the enrolment of 305 patients in the current Phase 2b study of NYX-2925 in fibromyalgia. NYX-2925 is being studied in 305 patients with fibromyalgia in a randomized, double-blind, placebo-controlled Phase 2 study.
Astellas Pharma Inc. has acquired bioelectronics start-up company Iota Biosciences, Inc. Astellas' Rx+ projects are estimated to accelerate in light of this acquisition.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?